These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22175694)

  • 21. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.
    Zou Z; Zhang W; Young D; Gleave MG; Rennie P; Connell T; Connelly R; Moul J; Srivastava S; Sesterhenn I
    Clin Cancer Res; 2002 May; 8(5):1172-7. PubMed ID: 12006534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
    Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
    Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
    Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
    Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor.
    Muddana SS; Price AM; MacBride MM; Peterson BR
    J Med Chem; 2004 Oct; 47(21):4985-8. PubMed ID: 15456242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
    Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
    Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T; Okabe S; Seimiya H
    Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
    Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
    Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
    Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance.
    Zhou J; Geng G; Shi Q; Sauriol F; Wu JH
    J Med Chem; 2009 Sep; 52(17):5546-50. PubMed ID: 19725582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
    Yan J; Xie B; Capodice JL; Katz AE
    Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.
    Yoshino H; Sato H; Shiraishi T; Tachibana K; Emura T; Honma A; Ishikura N; Tsunenari T; Watanabe M; Nishimoto A; Nakamura R; Nakagawa T; Ohta M; Takata N; Furumoto K; Kimura K; Kawata H
    Bioorg Med Chem; 2010 Dec; 18(23):8150-7. PubMed ID: 21050768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
    Wang LG; Ossowski L; Ferrari AC
    Oncogene; 2004 Jul; 23(30):5175-84. PubMed ID: 15156193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the androgen receptor activity by Coprinus comatus substances.
    Dotan N; Wasser SP; Mahajna J
    Nutr Cancer; 2011 Nov; 63(8):1316-27. PubMed ID: 21981678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piper cubeba targets multiple aspects of the androgen-signalling pathway. A potential phytotherapy against prostate cancer growth?
    Yam J; Kreuter M; Drewe J
    Planta Med; 2008 Jan; 74(1):33-8. PubMed ID: 18080233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells.
    Gunawardena K; Campbell LD; Meikle AW
    Cancer Detect Prev; 2005; 29(4):389-95. PubMed ID: 16139439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.
    Kinoyama I; Taniguchi N; Toyoshima A; Nozawa E; Kamikubo T; Imamura M; Matsuhisa A; Samizu K; Kawanimani E; Niimi T; Hamada N; Koutoku H; Furutani T; Kudoh M; Okada M; Ohta M; Tsukamoto S
    J Med Chem; 2006 Jan; 49(2):716-26. PubMed ID: 16420057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.